Latest Healthcare News

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

4DMedical has submitted its CT:VQ lung imaging technology for FDA clearance, aiming to disrupt the $1 billion US nuclear lung scan market with a non-nuclear, lower-cost alternative. Clinical studies show CT:VQ matches or exceeds existing nuclear imaging in accuracy and patient experience.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

Atomo Diagnostics has landed a significant $450,000 order to supply HIV self-tests for a federally funded Australian program aimed at increasing at-home testing among high-risk groups.

Prescient Therapeutics has reached a pivotal milestone by dosing the first patient in its Phase 2a clinical trial of PTX-100 for relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), aiming to evaluate safety and efficacy across multiple international sites.

Talius has deepened its partnership with Silverchain Group to pilot an AI voice assistant aimed at transforming home aged care services, starting with appointment scheduling in Western Australia and eyeing a national rollout.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.

Optiscan Imaging Ltd has reached a pivotal milestone with the completion of its cloud-based telepathology software MVP, enabling secure, real-time remote collaboration for digital pathology.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.